Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

This study is testing a new type of CAR-T cell therapy (immune cells engineered to attack cancer) that targets a protein called CD56, for people with relapsed or treatment-resistant NK/T-cell lymphoma or NK cell leukemia — rare and aggressive blood cancers. **You may be eligible if...** - You are between 18 and 70 years old - You have been diagnosed with NK/T-cell lymphoma or NK cell leukemia confirmed by pathology or flow cytometry - Your cancer has come back or stopped responding to prior treatments - You have received at least two prior lines of treatment - Your general health is well enough to tolerate this therapy **You may NOT be eligible if...** - You have not received prior treatment for your cancer - You have active serious infections (including HIV, hepatitis B or C) - You have other significant organ problems (heart, liver, kidneys) - You have had a recent stem cell transplant Talk to your doctor to see if this trial is right for you.